Identification of Facilitators and Barriers for the Management of Pediatric Asthma within School-based Clinics: A Mixed Methods Approach

Date Added
September 16th, 2023
PRO Number
Pro00130502
Researcher
Katherine Chike-Harris

List of Studies


Keywords
Asthma, Pediatrics
Summary

Pediatric asthma is not well controlled in SC and it's important to understand the facilitators and barriers to asthma care, especially in rural and underserved populations. Though school-based clinics provide quality asthma care to pediatric patients and has been shown to increase asthma control and decreased unnecessary health care utilization (i.e., emergency room), enrollment continues to be low. To identify and understand the facilitators and barriers to asthma care within school-based clinics, it is important to query caregivers (parents, grandparents, foster parents, legal guardians) and providers (doctors, APPs) to elicit their thoughts and opinions. This study will include caregiver and provider surveys and individual interviews to collect and analyze these thoughts and opinions.

Institution
MUSC
Recruitment Contact
Katherine Chike-Harris
843-792-4649
chikehar@musc.edu

An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency

Date Added
July 25th, 2023
PRO Number
Pro00130044
Researcher
Deborah Bowlby

List of Studies


Keywords
Pediatrics
Summary

Subjects entering this long-term safety extension (LTSE) study must have successfully participated in a pediatric LUM-201 GHD study through at least the 12-month visit and are eligible for continuation of treatment beyond Month 12, if applicable. Subjects may be enrolled into the LUM-201-02 study, having met all enrollment criteria, following successful completion of 12, 18, or 24 months of treatment in a pediatric LUM-201 GHD study.
Subjects who have met the AHV ≥ 6.7 growth criterion and have continued on treatment beyond the Month 12 visit in the LUM-201-01 trial may transition into the LUM-201-02 trial at Month 18 visit. For these subjects, AHV at Month 24 will be compared to AHV at Month 12, and if it is confirmed to be ≥ 80% of the Month 12 AHV, continued treatment with LUM-201 will be offered.

Institution
MUSC
Recruitment Contact
Terry Headley
843-792-4629
headleyt@musc.edu

Cold Atmospheric Plasma Device for the Treatment of Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients - Open-Label Extension Study

Date Added
June 6th, 2023
PRO Number
Pro00127338
Researcher
Lara Wine Lee

List of Studies


Keywords
Children's Health, Pediatrics, Skin
Summary

Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearance will be measured. Photographs and dermatologist impressions will be used to measure treatment response.

Institution
MUSC
Recruitment Contact
Courtney Rowley
843-792-9784
rowle@ musc

Neurobehavioral and Immune Effects of Citicoline in Youth Alcohol Use Disorder

Date Added
June 6th, 2023
PRO Number
Pro00128800
Researcher
Lindsay Squeglia

List of Studies